Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Published byDaniel Anderson Modified over 5 years ago

Similar presentations

Presentation on theme: "Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with."— Presentation transcript:

1 Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer.
Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Top, CT scans of a patient with metastatic colorectal cancer harboring an LMNA–NTRK1 rearrangement were recorded at baseline (March 2014), at the time of partial response to the pan-TRK inhibitor entrectinib (April 2014), and upon disease progression (July 2014). Bottom, longitudinal analysis of plasma ctDNA collected at different time points throughout the treatment. Red bars, absolute LMNA–NTRK1 copies in 1 mL of plasma; blue and black lines, NTRK1 p.G595R- and p.G667C-mutated alleles (%), respectively. Average ± SD of 3 independent experiments is reported. Mariangela Russo et al. Cancer Discov 2016;6:36-44 ©2016 by American Association for Cancer Research

Download ppt "Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with."

Similar presentations

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.
Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis  Karin Birkenkamp-Demtröder, Emil Christensen,

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis  Karin Birkenkamp-Demtröder, Emil Christensen,
Dose-escalation patient response.

Dose-escalation patient response.
Clonal evolution of resistance to sequential ALK inhibitor therapy.

Clonal evolution of resistance to sequential ALK inhibitor therapy.
Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.
Volume 73, Issue 4, Pages (April 2018)

Volume 73, Issue 4, Pages (April 2018)
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
A, baseline and 4-week PET scan from patient 2 (MET c

A, baseline and 4-week PET scan from patient 2 (MET c
Volume 147, Issue 4, Pages (April 2015)

Volume 147, Issue 4, Pages (April 2015)
by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff

by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff
Anna F. Farago, MD, PhD, Long P

Anna F. Farago, MD, PhD, Long P
Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.

Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
AKT dependence of ovarian cancer cell lines.

AKT dependence of ovarian cancer cell lines.
The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.
Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.
Anna F. Farago, MD, PhD, Long P

Anna F. Farago, MD, PhD, Long P

Similar presentations

Ads by Google